Chart Events
Performance Outlook
| Previous Close | 46.98 |
| Open | 46.98 |
| Bid | 46.88 x 1200 |
| Ask | 46.89 x 1300 |
| Day's Range | 46.84 - 46.92 |
| 52 Week Range | 42.63 - 57.82 |
| Volume | |
| Avg. Volume | 2,019,661 |
| Market Cap | 118.578B |
| Beta (5Y Monthly) | 0.46 |
| PE Ratio (TTM) | 11.84 |
| EPS (TTM) | 3.96 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.90 (4.04%) |
| Ex-Dividend Date | May 30, 2023 |
| 1y Target Est | 62.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SNY
Related Research
- SanofiAnalyst Report: SanofiSanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.RatingFair ValueEconomic Moatlast monthMorningstar
- Reuters
UPDATE 2-White House urges RSV immunization makers to meet demand
Senior Biden administration officials met with the makers of RSV immunizations for children this week to underscore the need for manufacturers such as Sanofi and AstraZeneca to urgently meet demand as winter approaches, the White House said on Tuesday. At a meeting at the White House on Monday, officials and manufacturers also agreed to plan now to meet next year's demand for the immunizations targeting respiratory syncytial virus, which generally causes mild, cold-like symptoms but can develop into severe illness in infants and older adults.
Investor's Business DailyRegeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Regeneron and Sanofi said Monday their blockbuster drug, Dupixent, significantly improved symptoms COPD symptoms.
FortuneHow the high-stakes world of Formula 1 racing inspired Sanofi CEO Paul Hudson to deliver more medicines
Hudson sought to emulate the efficiency of a race car team that recently set the world record for quickest pit stop.
